OMER News and Press, Omeros Corporation From 12/05/19

Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated ...

Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated ...

Schmitt Industries (NASDAQ: SMIT ) +13%  on $2M stock repurchase plan . More news on: Schmitt Industries, Inc., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Stocks on the move, Read more ...

Omeros (NASDAQ: OMER ) is up  4%  premarket on light volume in response to positive data from a pivotal  Phase 2 clinical trial evaluating narsoplimab (OMS721) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (blood clots in tiny...

– 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA; 68 Percent Primary-Endpoint Complete Response Rate for Those Who Received Protocol-Specified Treatment of At Least 4 Weeks of Dosing &...

Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The positively received and well-attended presentation about the company’s ce...

-- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals. The studies were c...

Omeros ( OMER ) is one of my favorite speculative biotech picks. This article reviews my current thinking on its prospects coming out of its recent Q3 earnings CC. Omeros has been a challenging hold of late as its share price forms jagged peaks only to soon fall in exhaustion from the effort...

Image source: The Motley Fool. Omeros   (NASDAQ: OMER) Q3 2019 Earnings Call Nov 12, 2019 , 4:30 p.m. ET Operator Continue reading

Omeros Corporation (OMER) Q3 2019 Earnings Conference Call November 12, 2019 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Conference Call Participants ...